Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
dc.contributor.author | Sprinz, Eduardo | pt_BR |
dc.contributor.author | Luz, Ana Júlia Bretanha | pt_BR |
dc.contributor.author | Weyh, Julia Poeta | pt_BR |
dc.contributor.author | Linden, Rafael | pt_BR |
dc.contributor.author | Antunes, Marina Venzon | pt_BR |
dc.contributor.author | Caminha, Luiza Isola | pt_BR |
dc.date.accessioned | 2015-12-16T02:39:59Z | pt_BR |
dc.date.issued | 2013 | pt_BR |
dc.identifier.issn | 1413-8670 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/131154 | pt_BR |
dc.description.abstract | To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia). Design: Cross-sectional study where 69 subjects were consecutively enrolled between April and November, 2011. Methods: Patients had to be on atazanavir for at least six months, undetectable viral load for a period equal to or longer than 12 months, T CD4+ lymphocyte count higher than 200 cells/mm3, and aged between 18 years and 70 years old. Exclusion criteria were pregnancy, any neurologic disease, active opportunistic disease, hepatitis or cancer. Atazanavir plasma levels were measured by ultra-performance liquid chromatography. Results and discussion: Overall, 54 patients (mean age of 47 years and 50% women) were included in the analysis. Those without ritonavir (unboosted atazanavir) had statistically lower plasma concentrations than those with ritonavir boosted atazanavir (p = 0.001) and total and indirect bilirubin were statistically associated with plasma concentration of atazanavir (r = 0.32 and r = 0.33 respectively; p < 0.05 in both cases). No statistical association was found among gender, ethnicity, age, weight, body mass index (BMI), lipid profile, and the plasma concentration of atazanavir. Conclusion: In summary, as expected, concomitant ritonavir use was the only factor associated with atazanavir plasma levels. Prospective studies with a larger sample size might help to observe an association of atazanavir concentrations to other characteristics such as body weight, since the p-value showed to be close to significance (p = 0.068). | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | The Brazilian journal of infectious diseases. Vol. 17, n. 6 (nov./dez. 2013), p. 657–660 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Inibidores da protease HIV | pt_BR |
dc.subject | Atazanavir | en |
dc.subject | Antirretrovirais | pt_BR |
dc.subject | Plasma levels | en |
dc.subject | Ritonavir | pt_BR |
dc.subject | Drug concentration | en |
dc.subject | Ritonavir | en |
dc.subject | HIV | pt_BR |
dc.subject | Lipid profile | en |
dc.title | Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 000950263 | pt_BR |
dc.type.origin | Nacional | pt_BR |
Files in this item
This item is licensed under a Creative Commons License
-
Journal Articles (39334)Health Sciences (10581)